• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

In search of the Holy Grail in atopic dermatitis: Will dupilumab become the first disease-modifying atopic dermatitis drug?

作者信息

Bieber Thomas

机构信息

Department of Dermatology and Allergy, University Hospital, Bonn, Germany; Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland; Davos Biosciences, Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland.

出版信息

J Allergy Clin Immunol. 2023 Mar;151(3):694-696. doi: 10.1016/j.jaci.2022.12.824. Epub 2023 Jan 21.

DOI:10.1016/j.jaci.2022.12.824
PMID:36693477
Abstract
摘要

相似文献

1
In search of the Holy Grail in atopic dermatitis: Will dupilumab become the first disease-modifying atopic dermatitis drug?寻找特应性皮炎的圣杯：度普利尤单抗会成为首个改善病情的特应性皮炎药物吗？
J Allergy Clin Immunol. 2023 Mar;151(3):694-696. doi: 10.1016/j.jaci.2022.12.824. Epub 2023 Jan 21.
2
Combination treatment with monoclonal antibodies: Dupilumab and ustekinumab for the treatment of severe atopic dermatitis and Crohn disease.单克隆抗体联合治疗：度普利尤单抗和优特克单抗用于治疗重度特应性皮炎和克罗恩病。
Australas J Dermatol. 2024 Feb;65(1):63-66. doi: 10.1111/ajd.14185. Epub 2023 Nov 6.
3
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.度普利尤单抗治疗青少年中重度特应性皮炎的临床意义：一项随机临床试验的事后分析。
Am J Clin Dermatol. 2020 Feb;21(1):119-131. doi: 10.1007/s40257-019-00478-y.
4
Severe atopic dermatitis and dupilumab.重度特应性皮炎与度普利尤单抗
Rev Assoc Med Bras (1992). 2023 Feb 17;69(1):2-6. doi: 10.1590/1806-9282.023D691. eCollection 2023.
5
Safety of dupilumab in patients with atopic dermatitis: expert opinion.治疗特应性皮炎患者的度普利尤单抗的安全性：专家意见。
Expert Opin Drug Saf. 2021 Sep;20(9):997-1004. doi: 10.1080/14740338.2021.1939673. Epub 2021 Jun 19.
6
Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?度普利尤单抗在特应性皮炎得到控制的特应性患者中减量：一种安全有效的做法？
J Eur Acad Dermatol Venereol. 2023 May;37(5):e691-e692. doi: 10.1111/jdv.18908. Epub 2023 Feb 6.
7
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
8
Dupilumab with concomitant Janus kinase inhibitor: a novel treatment strategy for atopic dermatitis with poor response to dupilumab.度普利尤单抗联合 Janus 激酶抑制剂：一种针对对度普利尤单抗反应不佳的特应性皮炎的新型治疗策略。
Br J Dermatol. 2022 Nov;187(5):828-830. doi: 10.1111/bjd.21776. Epub 2022 Aug 25.
9
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).度普利尤单抗治疗青少年中重度特应性皮炎的长期疗效和安全性：III 期开放标签扩展试验（LIBERTY AD PED-OLE）的第 52 周结果。
Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14.
10
Reported Pregnancy Outcomes in Women With Severe Atopic Dermatitis Treated With Dupilumab: A Systematic Review.使用度普利尤单抗治疗的重度特应性皮炎女性的妊娠结局报告：一项系统评价
J Cutan Med Surg. 2023 Mar-Apr;27(2):177-178. doi: 10.1177/12034754231152223. Epub 2023 Jan 31.

引用本文的文献

1
Atopic Dermatitis beyond Eczema: A Review on its Systemic Impact through Pruritus and Associated Comorbidities.超越湿疹的特应性皮炎：关于其通过瘙痒及相关合并症产生的全身影响的综述
Clin Rev Allergy Immunol. 2025 Jul 16;68(1):66. doi: 10.1007/s12016-025-09075-w.
2
Comparative Real-World Analysis of Baseline Demographic Characteristics and Comorbidities in Atopic Dermatitis Patients Initiating Biologics Versus JAK Inhibitors.启动生物制剂与JAK抑制剂的特应性皮炎患者基线人口统计学特征和合并症的比较真实世界分析
J Clin Med. 2025 Feb 15;14(4):1291. doi: 10.3390/jcm14041291.
3
Severe Asthma in School-Age Children: An Updated Appraisal on Biological Options and Challenges in This Age Group.
学龄儿童重度哮喘：该年龄组生物学选择与挑战的最新评估
Children (Basel). 2025 Jan 29;12(2):167. doi: 10.3390/children12020167.
4
Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative Review.白细胞介素-4与特应性皮炎：为何重要？一篇叙述性综述。
Dermatol Ther (Heidelb). 2025 Mar;15(3):579-597. doi: 10.1007/s13555-025-01352-y. Epub 2025 Feb 10.
5
Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases.2 型炎症期间的神经免疫相互作用：特应性疾病的症状、机制和治疗靶点。
J Allergy Clin Immunol. 2024 Apr;153(4):879-893. doi: 10.1016/j.jaci.2023.08.017. Epub 2023 Aug 25.
6
Disease modification in inflammatory skin disorders: opportunities and challenges.炎症性皮肤疾病的疾病修饰：机遇与挑战。
Nat Rev Drug Discov. 2023 Aug;22(8):662-680. doi: 10.1038/s41573-023-00735-0. Epub 2023 Jul 13.